000137589 001__ 137589
000137589 005__ 20240229105111.0
000137589 0247_ $$2doi$$a10.1073/pnas.1720564115
000137589 0247_ $$2pmid$$apmid:29895693
000137589 0247_ $$2pmc$$apmc:PMC6042091
000137589 0247_ $$2ISSN$$a0027-8424
000137589 0247_ $$2ISSN$$a1091-6490
000137589 0247_ $$2altmetric$$aaltmetric:43641438
000137589 037__ $$aDKFZ-2018-01469
000137589 041__ $$aeng
000137589 082__ $$a000
000137589 1001_ $$0P:(DE-HGF)0$$aCorreia, Margareta P$$b0$$eFirst author
000137589 245__ $$aDistinct human circulating NKp30+FcεRIγ+CD8+ T cell population exhibiting high natural killer-like antitumor potential.
000137589 260__ $$aWashington, DC$$bNational Acad. of Sciences$$c2018
000137589 3367_ $$2DRIVER$$aarticle
000137589 3367_ $$2DataCite$$aOutput Types/Journal article
000137589 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659613705_16657
000137589 3367_ $$2BibTeX$$aARTICLE
000137589 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000137589 3367_ $$00$$2EndNote$$aJournal Article
000137589 520__ $$aCD8+ T cells are considered prototypical cells of adaptive immunity. Here, we uncovered a distinct CD8+ T cell population expressing the activating natural killer (NK) receptor NKp30 in the peripheral blood of healthy individuals. We revealed that IL-15 could de novo induce NKp30 expression in a population of CD8+ T cells and drive their differentiation toward a broad innate transcriptional landscape. The adaptor FcεRIγ was concomitantly induced and was shown to be crucial to enable NKp30 cell-surface expression and function in CD8+ T cells. FcεRIγ de novo expression required promoter demethylation and was accompanied by acquisition of the signaling molecule Syk and the 'innate' transcription factor PLZF. IL-15-induced NKp30+CD8+ T cells exhibited high NK-like antitumor activity in vitro and were able to synergize with T cell receptor signaling. Importantly, this population potently controlled tumor growth in a preclinical xenograft mouse model. Our study, while blurring the borders between innate and adaptive immunity, reveals a unique NKp30+FcεRIγ+CD8+ T cell population with high antitumor therapeutic potential.
000137589 536__ $$0G:(DE-HGF)POF3-314$$a314 - Tumor immunology (POF3-314)$$cPOF3-314$$fPOF III$$x0
000137589 588__ $$aDataset connected to CrossRef, PubMed,
000137589 650_7 $$2NLM Chemicals$$aFCER1G, human
000137589 650_7 $$2NLM Chemicals$$aNCR3 protein, human
000137589 650_7 $$2NLM Chemicals$$aNatural Cytotoxicity Triggering Receptor 3
000137589 650_7 $$2NLM Chemicals$$aReceptors, Fc
000137589 7001_ $$0P:(DE-He78)6459232320662d60ee842fd348128d87$$aStojanovic, Ana$$b1$$udkfz
000137589 7001_ $$0P:(DE-He78)5b10e57ed1df98e2fd31edbdeed985ba$$aBauer, Katharina$$b2$$udkfz
000137589 7001_ $$0P:(DE-He78)5482b9f7e4c4ff6a3a4d7c860a1bce61$$aJuraeva, Dilafruz$$b3$$udkfz
000137589 7001_ $$aTykocinski, Lars-Oliver$$b4
000137589 7001_ $$aLorenz, Hanns-Martin$$b5
000137589 7001_ $$0P:(DE-He78)fc949170377b58098e46141d95c72661$$aBrors, Benedikt$$b6$$udkfz
000137589 7001_ $$0P:(DE-He78)d2b4dd8bdffe4aaa0f5e30e91587766f$$aCerwenka, Adelheid$$b7$$eLast author$$udkfz
000137589 773__ $$0PERI:(DE-600)1461794-8$$a10.1073/pnas.1720564115$$gVol. 115, no. 26, p. E5980 - E5989$$n26$$pE5980 - E5989$$tProceedings of the National Academy of Sciences of the United States of America$$v115$$x1091-6490$$y2018
000137589 909CO $$ooai:inrepo02.dkfz.de:137589$$pVDB
000137589 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6459232320662d60ee842fd348128d87$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000137589 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5b10e57ed1df98e2fd31edbdeed985ba$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000137589 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5482b9f7e4c4ff6a3a4d7c860a1bce61$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000137589 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fc949170377b58098e46141d95c72661$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000137589 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d2b4dd8bdffe4aaa0f5e30e91587766f$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000137589 9131_ $$0G:(DE-HGF)POF3-314$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTumor immunology$$x0
000137589 9141_ $$y2018
000137589 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium
000137589 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000137589 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000137589 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000137589 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bP NATL ACAD SCI USA : 2015
000137589 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000137589 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000137589 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000137589 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000137589 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000137589 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000137589 915__ $$0StatID:(DE-HGF)1060$$2StatID$$aDBCoverage$$bCurrent Contents - Agriculture, Biology and Environmental Sciences
000137589 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000137589 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record
000137589 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000137589 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bP NATL ACAD SCI USA : 2015
000137589 9201_ $$0I:(DE-He78)D080-20160331$$kD080$$lNachwuchsgruppe Angeborene Immunität$$x0
000137589 9201_ $$0I:(DE-He78)G200-20160331$$kG200$$lAngewandte Bioinformatik$$x1
000137589 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000137589 980__ $$ajournal
000137589 980__ $$aVDB
000137589 980__ $$aI:(DE-He78)D080-20160331
000137589 980__ $$aI:(DE-He78)G200-20160331
000137589 980__ $$aI:(DE-He78)L101-20160331
000137589 980__ $$aUNRESTRICTED